Report on Biological Warfare Defense Vaccine Research & Development Programs

摘要

Section 218 of the Floyd D. Spence National Defense Authorization Act for Fiscal Year 2001, Public Law (PL) 106-398 (at Appendix A) requires the submission of a report to the congressional defense committees on the acquisition of biological defense vaccines for the Department of Defense (DoD). As required by section 218, PL 106-398, this report addresses: 1) the implications of relying on the commercial sector to meet the DoD's biological defense vaccine requirements; 2) a design for a government-owned, contractor-operated (GOCO) vaccine production facility; 3) preliminary cost estimates and schedule for the facility; 4) consultation with the Surgeon General on the utility of such a facility for the production of vaccines for the civilian sector and the impact of civilian production on meeting Armed Forces needs and facility operating costs; and 5) the impact of international vaccine requirements and the production of vaccines to meet those requirements on meeting Armed Forces needs and facility operating costs. Since 1998, senior leadership has amplified the focus on resolution of difficulties in securing a ready and reliable access to safe and effective vaccines for use against biological warfare agents.